The DOI matches its Crossref record; 155 of the 155 references it cites were found in a registry or an index.
The role of p53 in cancer drug resistance and targeted chemotherapy
Open accessAbstract
// Karin Hientz 1 , André Mohr 1 , Dipita Bhakta-Guha 2 and Thomas Efferth 1 1 Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany 2 School of Chemical and Bio Technology, SASTRA University, Tamil Nadu, India Correspondence to: Thomas Efferth, email: // Keywords : cytotoxic chemotherapy, drug resistance, medicinal chemistry, prognostic factors, targeted chemotherapy Received : July 10, 2016 Accepted : October 13, 2016 Published : November 19, 2016 Abstract Cancer has long been a grievous disease complicated by innumerable players aggravating its cure. Many clinical studies demonstrated the prognostic relevance of the tumor suppressor protein p53 for many human tumor types. Overexpression of mutated p53 with reduced or abolished function is often connected to resistance to standard medications, including cisplatin, alkylating agents (temozolomide), anthracyclines, (doxorubicin), antimetabolites (gemcitabine), antiestrogenes (tamoxifen) and EGFR-inhibitors (cetuximab). Such mutations in the TP53 gene are often accompanied by changes in the conformation of the p53 protein. Small molecules that restore the wild-type conformation of p53 and, consequently, rebuild its proper function have been identified. These promising agents include PRIMA-1, MIRA-1, and several derivatives of the thiosemicarbazone family. In addition to mutations in p53 itself, p53 activity may be also be impaired due to alterations in p53’s regulating proteins such as MDM2. MDM2 functions as primary cellular p53 inhibitor and deregulation of the MDM2/p53-balance has serious consequences. MDM2 alterations often result in its overexpression and therefore promote inhibition of p53 activity. To deal with this problem, a judicious approach is to employ MDM2 inhibitors. Several promising MDM2 inhibitors have been described such as nutlins, benzodiazepinediones or spiro-oxindoles as well as novel compound classes such as xanthone derivatives and trisubstituted aminothiophenes. Furthermore, even naturally derived inhibitor compounds such as α-mangostin, gambogic acid and siladenoserinols have been discovered. In this review, we discuss in detail such small molecules that play a pertinent role in affecting the p53-MDM2 signaling axis and analyze their potential as cancer chemotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091
Role of nrf2 in oxidative stress and toxicity
Ma, Q. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140320 · Cited by 4,903
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 1×
“It is interesting to note that the majority of mutations occur in the core domain of p53, which usually harbors sequence-specific DNA binding activity (residues 102-292) [26].”
BackgroundKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“Firstly, MIRA-1 treatment induced ER-signaling [85-87] by triggering activation of PERK (protein kinase R-like endoplasmic reticulum kinase), one of the ER stress sensors.”
BackgroundThe complexity of p53 modulation: emerging patterns from divergent signals
Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,314
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
Dynamics of the p53-Mdm2 feedback loop in individual cells
Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,013
Regulation of p53 in response to DNA damage
Lakin, N. D., & Jackson, S. P. (1999) · Oncogene · doi:10.1038/sj.onc.1203015 · Cited by 987
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., et al. (1997) · PubMed · Cited by 867
The p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765
Medicinal properties of mangosteen (Garcinia mangostana)
Pedraza-Chaverri, J., Cárdenas-Rodríguez, N., Orozco-Ibarra, M., & Pérez-Rojas, J. M. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.07.024 · Cited by 763
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
Structural Biology of the Tumor Suppressor p53
Joerger, A. C., & Fersht, A. R. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.060806.091238 · Cited by 693
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Solomon, J. M., Pasupuleti, R., Xu, L., McDonagh, T., Curtis, R., DiStefano, P. S., & Huber, L. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.28-38.2006 · Cited by 486
Xanthone Derivatives: New Insights in Biological Activities
Pinto, M. M. M., Sousa, M. E., & Nascimento, M. S. J. (2005) · Current Medicinal Chemistry · doi:10.2174/092986705774370691 · Cited by 481
p53 Research: The Past Thirty Years and the Next Thirty Years
Lane, D., & Levine, A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000893 · Cited by 454
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
p53: Guardian of the Genome and Policeman of the Oncogenes
Efeyan, A., & Serrano, M. (2007) · Cell Cycle · doi:10.4161/cc.6.9.4211 · Cited by 439
Fuertes, M., Castilla, J., Alonso, C., & Pérez, J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368484 · Cited by 432
Discovery and Cocrystal Structure of Benzodiazepinedione HDM2 Antagonists That Activate p53 in Cells
Grasberger, B. L., Lu, T., Schubert, C., Parks, D. J., Carver, T. E., Koblish, H. K., Cummings, M. D., LaFrance, L. V., Milkiewicz, K. L., Calvo, R. R., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049137g · Cited by 432
p53: 25 years after its discovery
Hofseth, L. J., Hussain, S. P., & Harris, C. C. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.009 · Cited by 431
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
Schnitt, S. J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.33 · Cited by 419
Yu, Y., Kalinowski, D. S., Kovacevic, Z., Siafakas, A. R., Jansson, P. J., Stefani, C., Lovejoy, D. B., Sharpe, P. C., Bernhardt, P. V., & Richardson, D. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900552r · Cited by 397
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
Stress Signals Utilize Multiple Pathways To Stabilize p53
Ashcroft, M., Taya, Y., & Vousden, K. H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3224-3233.2000 · Cited by 356
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 353
Multiple roles of the tumor suppressor p53
Bargonetti, J., & Manfredi, J. J. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200201000-00015 · Cited by 332
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
SIRT1, Is It a Tumor Promoter or Tumor Suppressor?
Deng, C.-X. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.147 · Cited by 321
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Hermisson, M., Klumpp, A., Wick, W., Wischhusen, J., Nagel, G., Roos, W., Kaina, B., & Weller, M. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03583.x · Cited by 311
Zhao, Y., Yu, S., Sun, W., Liu, L., Lu, J., McEachern, D., Shargary, S., Bernard, D., Li, X., Zhao, T., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4005708 · Cited by 290
Molecular Mechanisms of Estrogen Action: Selective Ligands and Receptor Pharmacology
Katzenellenbogen, B. S., Choi, I., Delage-Mourroux, R., Ediger, T. R., Martini, P. G. V., Montano, M., Sun, J., Weis, K., & Katzenellenbogen, J. A. (2000) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00104-7 · Cited by 289
The p53 and Mdm2 families in cancer
Michael, D. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00264-7 · Cited by 284
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283
Reardon, J. T., Vaisman, A., Chaney, S. G., & Sancar, A. (1999) · PubMed · Cited by 281
Mdm2: keeping p53 under control
Piette, J., Neel, H., & Maréchal, V. (1997) · Oncogene · doi:10.1038/sj.onc.1201432 · Cited by 266
Mirzayans, R., Andrais, B., Scott, A., & Murray, D. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/170325 · Cited by 257
Targeting p53 for Novel Anticancer Therapy
Wang, Z., & Sun, Y. (2010) · Translational Oncology · doi:10.1593/tlo.09250 · Cited by 250
Kojima, K., Konopleva, M., McQueen, T., O'Brien, S., Plunkett, W., & Andreeff, M. (2006) · Blood · doi:10.1182/blood-2005-12-5148 · Cited by 245
Coll-Mulet, L., Iglesias-Serret, D., Santidrián, A. F., Cosialls, A. M., de Frias, M., Castaño, E., Campàs, C., Barragán, M., de Sevilla, A. F., Domingo, A., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3273 · Cited by 234
mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation
Mendrysa, S. M., McElwee, M. K., Michalowski, J., O'Leary, K. A., Young, K. M., & Perry, M. E. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.2.462-473.2003 · Cited by 234
Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells
Huang, Y., & Sadée, W. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.032 · Cited by 230
A common gain of function of p53 cancer mutants in inducing genetic instability
Liu, D. P., Song, H., & Xu, Y. (2010) · Oncogene · doi:10.1038/onc.2009.376 · Cited by 219
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Rusch, V. W., Klimstra, D. S., Venkatraman, E. S., Oliver, J., Martini, N., Gralla, R. J., Kris, M. G., & Dmitrovsky, E. (1995) · PubMed · Cited by 194
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
Hainaut, P. L., & Milner, J. (1993) · PubMed · Cited by 182
Antiestrogens: Mechanisms of action and resistance in breast cancer
Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., & McInerney, E. M. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005835428423 · Cited by 179
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 176
Parks, D. J., LaFrance, L. V., Calvo, R. R., Milkiewicz, K. L., Gupta, V., Lattanze, J., Ramachandren, K., Carver, T. E., Petrella, E. C., Cummings, M. D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.009 · Cited by 167
Huether, A., Höpfner, M., Baradari, V., Schuppan, D., & Scherübl, H. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.007 · Cited by 166
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 165
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 162
Estrogen Receptor-α Binds p53 Tumor Suppressor Protein Directly and Represses Its Function
Liu, W., Konduri, S. D., Bansal, S., Nayak, B. K., Rajasekaran, S. A., Karuppayil, S. M., Rajasekaran, A. K., & Das, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600001200 · Cited by 160
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters
Okabe, M., Szakács, G., Reimers, M. A., Suzuki, T., Hall, M. D., Abe, T., Weinstein, J. N., & Gottesman, M. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0539 · Cited by 158
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine
Fiorini, C., Cordani, M., Padroni, C., Blandino, G., Agostino, S. D., & Donadelli, M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.003 · Cited by 152
Geisler, S. B., Børresen‐Dale, A., Johnsen, H., Aas, T., Geisler, J., Akslen, L. A., Anker, G. B., & Lønning, P. E. (2003) · PubMed · Cited by 151
Jiang, C. C., Lucas, K. M., Avery‐Kiejda, K. A., Wade, M., de Bock, C. E., Thorne, R. F., Allen, J., Hersey, P., & Zhang, X. D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0349 · Cited by 150
Shibata, M., Iinuma, M., Morimoto, J., Kurose, H., Akamatsu, K., Okuno, Y., Akao, Y., & Otsuki, Y. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-69 · Cited by 149
MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death
Barbieri, E., Mehta, P. S., Chen, Z., Zhang, L., Slack, A., Berg, S. L., & Shohet, J. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0305 · Cited by 147
Smith, N. D., Rubenstein, J. N., Eggener, S. E., & Kozlowski, J. M. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000056085.58221.80 · Cited by 147
Gómez-Lázaro, M., Galindo, M. F., Concannon, C. G., Segura, M. F., Fernández-Gómez, F.-J., Llecha, N., Comella, J. X., Prehn, J. H. M., & Jordán, J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05115.x · Cited by 143
Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Tung, M., Lin, P.-L., Wang, Y.-C., He, T.-Y., Lee, M.-C., Yeh, S.-D., Chen, C., & Lee, H. (2015) · Oncotarget · doi:10.18632/oncotarget.6150 · Cited by 140
Pharmacological reactivation of mutant p53: from protein structure to the cancer patient
Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 134
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Chemistry and Biology of the Caged Garcinia Xanthones
Chantarasriwong, O., Batova, A., Chavasiri, W., & Theodorakis, E. A. (2010) · Chemistry - A European Journal · doi:10.1002/chem.201000741 · Cited by 129
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
Huang, S., Benavente, S., Armstrong, E. A., Li, C., Wheeler, D. L., & Harari, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0128 · Cited by 116
The p53-Estrogen Receptor Loop in Cancer
Berger, C. E., Qian, Y., & Chen, X. (2013) · Current Molecular Medicine · doi:10.2174/15665240113139990065 · Cited by 110
Bill, K. L. J., Garnett, J., Meaux, I., Ma, X., Creighton, C. J., Bolshakov, S. V., Barrière, C., Debüssche, L., Lazar, A. J., Prudner, B. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1522 · Cited by 109
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 103
Expression of a non‐functional p53 affects the sensitivity of cancer cells to gemcitabine
Galmarini, C. M., Clarke, M. L., Falette, N., Puisieux, A., Mackey, J. R., & Dumontet, C. (2001) · International Journal of Cancer · doi:10.1002/ijc.1628 · Cited by 100
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation
Jiang, M., Pabla, N., Murphy, R. F., Yang, T., Yin, X.-M., Degenhardt, K., White, E., & Dong, Z. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m606928200 · Cited by 97
Blough, M. D., Beauchamp, D. C., Westgate, M. R., Kelly, J. J., & Cairncross, J. G. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0283-9 · Cited by 94
Formation of Disulfide Bond in p53 Correlates with Inhibition of DNA Binding and Tetramerization
Sun, X. Z., Vinci, C., Makmura, L., Han, S., Tran, D., Nguyen, J., Hamann, M. J., Grazziani, S., Sheppard, S., Gutova, M., et al. (2003) · Antioxidants and Redox Signaling · doi:10.1089/152308603770310338 · Cited by 91
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Iancu-Rubin, C., Mosoyan, G., Glenn, K., Gordon, R. E., Nichols, G. L., & Hoffman, R. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2013.11.012 · Cited by 90
Lin, X., & Howell, S. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0491 · Cited by 89
LaRusch, G. A., Jackson, M. W., Dunbar, J. D., Warren, R. S., Donner, D. B., & Mayo, L. D. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2710 · Cited by 89
TP53 Status and Response to Treatment in Breast Cancers
Varna, M., Bousquet, G., Plassa, L., Bertheau, P., & Janin, A. (2011) · BioMed Research International · doi:10.1155/2011/284584 · Cited by 87
Therapeutic targeting of p53 by small molecules
Selivanova, G. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.02.006 · Cited by 86
Gu, H.-Y., Wang, X., Rao, S., Wang, J., Zhao, J., Ren, F. L., Mu, R., Yang, Y., Qi, Q., Liu, W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0212 · Cited by 84
Gourdier, I., Rio, M. D., Crabbé, L., Candeil, L., Copois, V., Ychou, M., Auffray, C., Martineau, P., Mechti, N., Pommier, Y. G., et al. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03347-1 · Cited by 83
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Kim, K. W., Albert, J. M., Hallahan, D. E., & Lü, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 83
Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells
Sauer, L., Gitenay, D., Vo, C., & Baron, V. T. (2010) · Oncogene · doi:10.1038/onc.2010.24 · Cited by 81
Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA
Zhao, C. Y., Grinkevich, V., Nikulenkov, F., Bao, W., & Selivanova, G. (2010) · Cell Cycle · doi:10.4161/cc.9.9.11545 · Cited by 79
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
Parks, D. J., LaFrance, L. V., Calvo, R. R., Milkiewicz, K. L., Marugán, J., Raboisson, P., Schubert, C., Koblish, H. K., Zhao, S., Franks, C. F., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.055 · Cited by 77
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53
Supiot, S., Hill, R. P., & Bristow, R. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0442 · Cited by 77
Pecháčková, S., Burdová, K., Benada, J., Kleiblová, P., Jeníková, G., & Macůrek, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7363 · Cited by 77
Gadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75
Xia, M., Knezevic, D., Tovar, C., Huang, B., Heimbrook, D. C., & Vassilev, L. T. (2008) · Cell Cycle · doi:10.4161/cc.7.11.5929 · Cited by 75
Deben, C., Wouters, A., de Beeck, K. O., van Den Bossche, J., Jacobs, J., Zwaenepoel, K., Peeters, M., Van Meerbeeck, J., Lardon, F., Rolfo, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4433 · Cited by 73
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
Knappskog, S., Chrisanthar, R., Løkkevik, E., Anker, G. B., Østenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., Leirvaag, B., Miletić, H., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3147 · Cited by 72
Martínez, C., García‐Martín, E., Pizarro, R. M., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600494 · Cited by 67
Burmakin, M., Shi, Y., Hedström, E., Kogner, P., & Selivanova, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2211 · Cited by 63
Weilbacher, A., Gutekunst, M., Oren, M., Aulitzky, W. E., & van der Kuip, H. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.284 · Cited by 62
Natsume, A., Wakabayashi, T., Ishii, D., Maruta, H., Fujii, M., Shimato, S., Ito, M., & Yoshida, J. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0520-x · Cited by 62
Discovery of a new small-molecule inhibitor of p53–MDM2 interaction using a yeast-based approach
Leão, M., Pereira, C., Bisio, A., Ciribilli, Y., Paiva, A. M. O., Machado, N., Palmeira, A., Fernandes, M. X., Sousa, E., Pinto, M. M. M., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.032 · Cited by 59
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R. (2014) · Apoptosis · doi:10.1007/s10495-014-0990-3 · Cited by 59
Dhayat, S. A., Mardin, W. A., Seggewiß, J., Ströse, A., Matuszcak, C., Hummel, R., Senninger, N. J., Mees, S. T., & Haier, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143755 · Cited by 59
MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms053 · Cited by 58
Wang, X., Chen, J., Liu, Y., You, C., & Mao, Q. (2012) · Neurological Sciences · doi:10.1007/s10072-012-1257-9 · Cited by 57
Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines
Pavillard, V., Agostini, C., Richard, S., Charasson, V., Montaudon, D., & Robert, J. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-001-0416-0 · Cited by 56
p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
Teoh, P. J., & Chng, W. J. (2014) · BioMed Research International · doi:10.1155/2014/717919 · Cited by 56
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 51
Raboisson, P., Marugán, J., Schubert, C., Koblish, H. K., Lu, T., Zhao, S., Player, M. R., Maroney, A. C., Reed, R. L., Huebert, N. D., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.018 · Cited by 50
Esfandiari, A., Hawthorne, T. A., Nakjang, S., & Lunec, J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0651 · Cited by 50
Li, X., Zhou, J., Chan, Z.-L., Chooi, J.-Y., Chen, Z., & Chng, W. J. (2015) · Oncotarget · doi:10.18632/oncotarget.5385 · Cited by 49
Cummings, M. D., Schubert, C., Parks, D. J., Calvo, R. R., LaFrance, L. V., Lattanze, J., Milkiewicz, K. L., & Lu, T. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00365.x · Cited by 48
Zhao, J., Qi, Q., Yang, Y., Gu, H.-Y., Lu, N., Liu, W., Wang, W., Qiang, L., Zhang, L., You, Q., et al. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.063 · Cited by 47
Khoury, K., & Dömling, A. S. S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651580 · Cited by 45
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman, A., Radovanovic, M., Wienken, M., Najafova, Z., Li, Y., & Dobbelstein, M. (2016) · Oncotarget · doi:10.18632/oncotarget.9302 · Cited by 44
Saha, M. N., Chen, Y., Chen, M.-H., Chen, G., & Chang, H. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.164 · Cited by 43
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Guo, Z., Zhuang, C., Zhu, L., Zhang, Y., Yao, J., Dong, G., Wang, S., Liu, Y., Chen, H., Sheng, C., et al. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.08.003 · Cited by 41
Sosin, A. M., Burger, A. M., Siddiqi, A., Abrams, J., Mohammad, R. M., & Al-Katib, A. M. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-57 · Cited by 40
Nakamura, Y., Kato, H., Nishikawa, T., Iwasaki, N., Suwa, Y., Rotinsulu, H., Losung, F., Maarisit, W., Mangindaan, R. E. P., Morioka, H., et al. (2013) · Organic Letters · doi:10.1021/ol3032363 · Cited by 39
Wang, W., Shangguan, S., Qiu, N., Hu, C., Zhang, L. J., & Hu, Y. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.03.061 · Cited by 37
Identification of FDA‐approved Drugs that Computationally Bind to MDM2
Warner, W. A., Sanchez, R., Dawoodian, A., Li, E., & Momand, J. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2012.01428.x · Cited by 36
Sun, S. H., Zheng, M., Ding, K., Wang, S., & Sun, Y. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.5841 · Cited by 36
Tumor Suppressor WWOX and p53 Alterations and Drug Resistance in Glioblastomas
Chiang, M., Chou, P., Wang, W., Sze, C., & Chang, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00043 · Cited by 34
D’Orazi, G., & Givol, D. (2012) · Cell Cycle · doi:10.4161/cc.21020 · Cited by 28
STAP-2 regulates c-Fms/M-CSF receptor signaling in murine macrophage Raw 264.7 cells
Ikeda, O., Sekine, Y., Kakisaka, M., Tsuji, S., Muromoto, R., Ohbayashi, N., Oritani, K., Yoshimura, A., & Matsuda, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.030 · Cited by 25
Effect of Y220C Mutation on p53 and Its Rescue Mechanism: A Computer Chemistry Approach
Rauf, S. M. A., Endou, A., Takaba, H., & Miyamoto, A. (2013) · The Protein Journal · doi:10.1007/s10930-012-9458-x · Cited by 19
Ma, T., Yamada, S., Ichwan, S. J. A., Iseki, S., Ohtani, K., Otsu, M., & Ikeda, M. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.11.161 · Cited by 19
Wang, W., Zhu, X., Hong, X., Zheng, L., Zhu, H., & Hu, Y. (2012) · MedChemComm · doi:10.1039/c2md20208e · Cited by 18
Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells
Samudio, I. J., Duvvuri, S. R., Clise-Dwyer, K., Watt, J. C., Mak, D. H. F., Kantarjian, H. M., Yang, D., Ruvolo, V. R., & Borthakur, G. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003731325 · Cited by 16
Cited by
Risk Factors and Preventions of Breast Cancer
Sun, Y.-S., Zhao, Z., Yang, Z.-N., Xu, F., Lu, H.-J., Zhu, Z.-Y., Shi, W., Jiang, J., Yao, P.-P., & Zhu, H.-P. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.21635 · Cited by 2,003
Role of p53 in the Regulation of Cellular Senescence
Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
Sang, W., Zhang, Z., Dai, Y., & Chen, X. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00896e · Cited by 405
Asymmetric organocatalysis: an enabling technology for medicinal chemistry
Han, B., He, X.-H., Liu, Y.-Q., He, G., Peng, C., & Li, J.-L. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00196a · Cited by 402
Metadata
- Authors
- Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-19
- Volume
- 8
- Issue
- 5
- Pages
- 8921-8946
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2552699553
- Cited by
- 587
- References
- 155
- FWCI
- 19.78
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.